Do drug- or device-induced effects on peak VO(2), 6-minute walk distance, and natriuretic peptides in short-term trials predict long-term therapeutic effects on mortality in patients with HFrEF?
Short-term improvements in surrogate markers like peak VO2, 6-minute walk distance, and natriuretic peptides do not reliably predict long-term mortality benefits in HFrEF trials.
This analysis, limited to trial level data from different therapeutic eras, suggests that drug- or device-induced effects on peak VO(2), 6MW, and natriuretic peptides found in short-term trials do not predict the corresponding average long-term therapeutic effects on mortality for patients with HF and left ventricular dysfunction.
Wessler et al. (Sat,) studied this question.